Sign in

    Gabrielle Ingoglia

    Research Analyst at Cantor Fitzgerald

    Gabrielle Ingoglia is an Equity Research Associate at Cantor Fitzgerald specializing in Healthcare Facilities, Managed Care, and Healthcare IT, with direct coverage of public companies such as DocGo and Universal Health Services. Since joining Cantor Fitzgerald in February 2024, Ingoglia has participated in in-depth earnings calls and research, building on her prior experience in Institutional Equity Sales at Wolfe Research and portfolio planning at Charles Schwab. She earned a Finance degree from Indiana University Bloomington, graduating in 2022, and leverages strong sector knowledge from her progression through research and sales roles in leading financial firms. Ingoglia is developing expertise on notable healthcare stocks and is expected to expand her coverage and industry recognition as she advances in the field.

    Gabrielle Ingoglia's questions to Acadia Healthcare Company (ACHC) leadership

    Gabrielle Ingoglia's questions to Acadia Healthcare Company (ACHC) leadership • Q1 2025

    Question

    Gabrielle Ingoglia, on for Sarah James at Cantor Fitzgerald, asked about any potential weather impacts on facilities and requested an update on the performance of the underperforming facilities mentioned in the previous quarter.

    Answer

    Executive Heather Dixon reported no material weather impacts. Executive Christopher Hunter stated the underperforming facilities performed in line with expectations, creating a 90 basis point headwind to same-facility patient growth in Q1. He reiterated the full-year $20 million EBITDA headwind assumption and noted the underperformance is correlated with local, not national, media coverage.

    Ask Fintool Equity Research AI

    Gabrielle Ingoglia's questions to DocGo (DCGO) leadership

    Gabrielle Ingoglia's questions to DocGo (DCGO) leadership • Q1 2025

    Question

    Gabrielle Ingoglia, on for Sarah James, questioned the discrepancy between the stated $100 million government revenue removal and the total guidance reduction of approximately $115 million. She also asked if the 2026 positive EBITDA projection excludes government contributions and if positive 2026 MA rates are driving more payer conversations.

    Answer

    CFO Norman Rosenberg clarified that the delta in the guidance reduction reflects prudence and a range for possibilities across all business lines, as the sum of individual segment targets ($325M) is higher than the midpoint of the new guidance range. CEO Lee Bienstock confirmed the 2026 positive EBITDA projection excludes potential upside from the municipal government vertical and affirmed that MA market dynamics are a tailwind, strengthening their value proposition with payers.

    Ask Fintool Equity Research AI

    Gabrielle Ingoglia's questions to Health Catalyst (HCAT) leadership

    Gabrielle Ingoglia's questions to Health Catalyst (HCAT) leadership • Q4 2024

    Question

    Gabrielle Ingoglia, on for Sarah James, inquired if the company has discussed the potential impact of healthcare policies, such as enhanced marketplace subsidies or site neutrality, with its end-market clients.

    Answer

    CEO Dan Burton responded that they maintain close contact with C-suite executives and are monitoring the policy environment. While clients are watching potential changes to research funding and Medicaid under the new administration, he stated that Health Catalyst has not observed any negative impact on its sales pipeline. He believes significant changes to popular programs like Medicaid would be complex to implement, mitigating near-term risk.

    Ask Fintool Equity Research AI

    Gabrielle Ingoglia's questions to UNIVERSAL HEALTH SERVICES (UHS) leadership

    Gabrielle Ingoglia's questions to UNIVERSAL HEALTH SERVICES (UHS) leadership • Q3 2024

    Question

    Gabrielle Ingoglia of Cantor Fitzgerald asked for the drivers behind the strong acute revenue per admission and for color on inpatient surgical trends.

    Answer

    Steve Filton attributed the strong revenue per admission to a difficult comparison with the prior year, which saw high volumes of lower-acuity, deferred procedures. As those catch-up procedures subsided, the acuity mix improved in Q3 2024. He noted that inpatient surgical volumes were soft, declining slightly, due to the same dynamic of strong but lower-acuity surgical catch-up in the prior-year quarter.

    Ask Fintool Equity Research AI